TOKYO — Japanese chemical and materials maker AGC said Thursday it has teamed up with an Osaka University-affiliated biotechnology company to help produce a coronavirus vaccine that offers a great mass-manufacturing advantage.
The DNA vaccine project is a collaboration between biotech venture AnGes and Takara Bio, which will handle most of the production work.
Seattle-based AGC Biologics, a subsidiary of AGC, will supply an intermediate material. The vaccine is expected to enter clinical trials as early as this summer.
Takara Bio looks to manufacture about 200,000 doses in a year. Unlike standard vaccines, which use live or inactivated pathogens to